Lateral Flow Technology and the Future of Point of Care Diagnostics

 
   Single User - $1,995
   Hard Copy Mail Delivery - $3,395
   Corporate License - $3,990
   Online Download plus 1 Hard Copy - $3,795



Loading...
Published Feb 1, 2007 | 184 Pages | Pub ID: KLI1393074

Lateral flow tests, also known as immunochromatographic strip (ICS) tests, offer dramatic benefits in the diagnostic process that point towards a robust market. LF tests are point of care tests that reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and manufacturing.

Rapid point of care testing devices will play an increasingly important role in the decentralization of medicine, where testing is moving away from hospitals and to pharmacies and even shopping malls, a trend that will fuel exponential growth. Despite these certain trends, competition is heavy and there are issues and trends affecting this market that new entrants need to be aware of.

Kalorama Information’s Lateral Flow Technology and the Future of Point of Care Diagnostics, is a perspective on the past and future of rapid clinical tests, is your guide to this increasingly crowded LF testing market place. Kalorama Information’s report cuts through the hype about the lateral flow point of care marketplace and provides a realistic assessment of this growing field. Every critical aspect of the LF market is addressed, including the following key topics:

  • The current sales figures and realistic projections for 2010.
  • The core factors driving LF testing revenues up.
  • The growing number of need-to-know companies in Lateral Flow Test devices.
  • The trends to watch that could increase sales predictions.
  • Expected gains to be made by LF POC devices over lab-based immunoassays across categories.
  • Obstacles that could trap new entrants.
  • An interview with the original developer of LF testing technology with his take on where this market is headed.

This report provides a realistic assessment acknowledging the reality of payors’ emphasis on cost/benefit analysis for new technologies. Current sales and predictions for 2010 sales are provided for the diabetes, oncology, cardiac marker, pregnancy and other LF test markets.

Kalorama’s unique and thorough research process provides an exhaustive analysis of this evolving market. Information was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals.

For the purpose of this study, Kalorama Information conducted telephone and email interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with device company representatives included marketing directors, division managers, and product development representatives.

In addition to superior coverage of the overall market, specific company profiles are included for the following device makers:

  • Becton, Dickinson and Company (BD)
  • Beckman Coulter Inc.
  • Biosite Incorporated
  • Instrumentation Laboratory (IL)
  • Inverness Medical Innovations, Inc.
  • Roche Diagnostics
  • The Second Tier
  • Acon Laboratories, Inc./Innovacon
  • Acrongenomics, Inc.
  • Addison-Davis Diagnostics, Inc. (ADDI)
  • ADIATEC
  • Akers Biosciences, Inc.
  • ALFA Scientific Designs, Inc.
  • Amedica Biotech
  • Ameritek, USA
  • Amic AB
  • Analyte Works Ltd. (formerly BioPreventative Ltd.)
  • Ani Biotech Oy
  • Asia-Lion Biotechnology Co., Ltd.
  • ASM Scientific Ltd
  • Avitar, Inc.
  • Axis-Shield plc
  • Binax, Inc.
  • bioLytical Laboratories Inc.
  • Biomerica Inc.
  • Biosafe Medical Technologies, Inc.
  • BioScan Screening Systems, Inc.
  • Boditech Med Inc.
  • BRAHMS
  • Branan Medical Corporation
  • Calypte Biomedical Corporation
  • Care Diagnostica International
  • Chembio Diagnostic Systems, Inc.
  • Cholestech Corporation
  • Chongqing Sungene Pharm. Co., Ltd.
  • Cibitest GmbH & Co. KG
  • Cis Biotech, Inc.
  • Coris BioConcept
  • Cozart Bioscience Ltd.
  • Diagenics International Corporation
  • Diagnostic Chemicals Ltd (DCL)
  • Enterix, Inc.
  • ESE Embedded Systems Engineering GmbH
  • EY Laboratories, Inc.
  • Genosis PLC
  • Genzyme Corporation
  • GlysBy snc
  • Grant Life Sciences Inc.
  • Gryphus Diagnostics, LLC
  • Hema Diagnostic Systems, LLC
  • ImmunoScience, Inc.
  • In Veritas Medical Diagnostics (IVMD UK Ltd)
  • IND Diagnostics Inc,
  • Innotrac Diagnostics Oy
  • Instant Technologies, Inc.
  • LifeAssays AB
  • Lifestream Technologies, Inc.
  • MagnaBioSciences LLC
  • Matritech
  • MAVAND Solutions GmbH
  • Medical Services International Inc.
  • Medifix Limited
  • MEDIWISS Analytic GmbH
  • MedMira Inc.
  • Meridian Bioscience, Inc.
  • Milenia Biotec GmbH
  • Mitsubishi Kagaku Iatron, Inc. (MKI)
  • Mossman Associates, Inc.
  • Nano-Ditech Corporation
  • Nanogen Inc.
  • OraSure Technologies, Inc.
  • Panbio Limited
  • Polymedco, Inc.
  • Preventis GmbH
  • Pria Diagnostics LLC
  • Princeton BioMeditech Corporation
  • Proteome Systems Ltd
  • Quidel Corporation
  • r-Biopharm AG
  • REAGENA Ltd
  • rennesens GmbH
  • Response Biomedical Corp.
  • Saliva Diagnostic Systems , Inc. (SDS)
  • Savyon Diagnostics
  • Shionogi & Co., Ltd.
  • Spectral Diagnostics Inc./Nanogen
  • Standard Diagnostics, Inc.
  • SureScreen Diagnostics, Ltd.
  • Synova Healthcare, Inc.
  • Talecris Biotherapeutics
  • ThyroTec, Inc.
  • Trinity Biotech plc
  • WaveSense, Inc
  • WayPoint Biomedical, Inc.
  • Xact Aid, Inc.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.